title: Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature.
abstract: Intravenous bisphosphonates are widely used to treat osteoporosis and bone metastasis in cancer patients The risk of hypocalcaemia is a rare but underestimated side effect of anti-resorptive treatment. Clinically apparent hypocalcaemia is mostly related to high-dose treatment with zoledronate and denosumab in cancer patients Particular caution is mandatory in all malnourished patients and patients with renal failure who are treated for either bone metastases or osteoporosis. To avoid serious hypocalcaemia, pre-treatment calcium and vitamin D status should be assessed and corrected if appropriate.
authors: Department of Endocrinology, Diabetology and Metabolism, Medical University Hospital Aarau, Switzerland.
authors: Veronika
authors: V
authors: Kreutle
authors: Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland.
authors: Claudine
authors: C
authors: Blum
authors: Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Switzerland.
authors: Christian
authors: C
authors: Meier
authors: Department of Endocrinology, Diabetology and Metabolism, Medical University Hospital Aarau, Switzerland.
authors: Miriam
authors: M
authors: Past
authors: Department of Endocrinology, Diabetology and Metabolism, Medical University Hospital Aarau, Switzerland.
authors: Beat
authors: B
authors: Müller
authors: Department of Endocrinology, Diabetology and Metabolism, Medical University Hospital Aarau, Switzerland.
authors: Philipp
authors: P
authors: Schütz
authors: Department of Endocrinology, Diabetology and Metabolism, Medical University Hospital Aarau, Switzerland.
authors: Katrin
authors: K
authors: Borm
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000097:blood / Q000627:therapeutic use; D004164:Diphosphonates / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000097:blood / Q000139:chemically induced* / Q000188:drug therapy; D007093:Imidazoles / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D014815:Vitamins / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D014815:Vitamins; D000077211:Zoledronic Acid; D002117:Calcitriol; D002118:Calcium